Drug-induced glomerular disease: Attention required!

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 7, 2015, Pages 1287-1290

  Radhakrishnan, Jai ^a   Perazella, Mark A ^b  

^a NewYork Presbyterian Hospital   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTITHROMBOCYTIC AGENT; CALCINEURIN INHIBITOR; CELECOXIB; HYDRALAZINE; INTERFERON; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PENICILLAMINE; PROCAINAMIDE; QUININE; SULFADIAZINE; THIENOPYRIDINE DERIVATIVE;

ANCA ASSOCIATED VASCULITIS; ANGIOGENESIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DAMAGE; DRUG INDUCED DISEASE; ENDOTHELIUM INJURY; GLOMERULAR INJURY; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; LUPUS LIKE SYNDROME; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PODOCYTE; PODOCYTE INJURY; SMOKING; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLOMERULONEPHRITIS; GLOMERULUS; IMMUNOLOGY; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLOMERULONEPHRITIS; HUMANS; KIDNEY GLOMERULUS; RISK ASSESSMENT; RISK FACTORS;

EID: 84936879488     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01010115     Document Type: Article

References (25)

1. Irey NS: Teaching monograph. Tissue reactions to drugs. Am J Pathol 82: 613–647, 1976
2. Merkel PA: Drug-induced vasculitis. Rheum Dis Clin North Am 27: 849–862, 2001
3. Markowitz, Bomback, Perazella: Clin J Am Soc Nephrol 7: 1292–1300, 2015
4. Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D’Agati VD: Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol 33: 826–835, 2002
5. Alpers CE, Biava CG: Idiopathic lobular glomerulonephritis (nodular mesangial sclerosis): A distinct diagnostic entity. Clin Nephrol 32: 68–74, 1989
6. Kuppachi S, Idris N, Chander PN, Yoo J: Idiopathic nodular glomerulosclerosis in a non-diabetic hypertensive smoker—case report and review of literature. Nephrol Dial Transplant 21: 3571–3575, 2006
7. Li W, Verani RR: Idiopathic nodular glomerulosclerosis: A clinicopathologic study of 15 cases. Hum Pathol 39: 1771–1776, 2008
8. Nasr SH, D’Agati VD: Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol 18: 2032–2036, 2007
9. George JN, Nester CM: Syndromes of thrombotic microangiopathy. N Engl J Med 371: 654–666, 2014
10. Zakarija A, Bennett C: Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 31: 681–690, 2005
11. Glezerman I, Kris MG, Miller V, Seshan S, Flombaum CD: Gemcitabine nephrotoxicity and hemolytic uremic syndrome: Report of 29 cases from a single institution. Clin Nephrol 71: 130–139, 2009
12. Hunt D, Kavanagh D, Drummond I, Weller B, Bellamy C, Overell J, Evans S, Jackson A, Chandran S: Thrombotic microangiopathy associated with interferon beta. N Engl JMed 370: 1270–1271, 2014
13. Orvain C, Augusto JF, Besson V, Marc G, Coppo P, Subra JF, Sayegh J: Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Int Urol Nephrol 46: 239–242, 2014
14. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC: VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 46: 439–448, 2010
15. Markowitz GS, Nasr SH, Stokes MB, D’Agati VD: Treatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 607–615, 2010
16. Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity. Kidney Int 74: 1385–1393, 2008
17. Brezin JH, Katz SM, Schwartz AB, Chinitz JL: Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 301: 1271–1273, 1979
18. Pirani CL, Valeri A, D’Agati V, AppelGB: Renal toxicity of nonsteroidal anti-inflammatory drugs. Contrib Nephrol 55: 159–175, 1987
19. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi MN, Helal I, Noël LH, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326–333, 2007
20. Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, Colvin RB, D’Agati VD: Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J AmSoc Nephrol 21: 163–172, 2010
21. Hogan, Markowitz, A Radhakrishnan: Clin J Am Soc Nephrol 7: 1301–1311, 2015
22. Rubin RL: Drug-induced lupus. Expert Opin Drug Saf 14: 361–378, 2015
23. Xiao X, Chang C: Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun 48-49: 66–72, 2014
24. Wiik A: Clinical and laboratory characteristics of druginduced vasculitic syndromes. Arthritis Res Ther 7: 191–192, 2005
25. Izzedine H, Launay-Vacher V, Bourry E, Brocheriou I, Karie S, Deray G: Drug-induced glomerulopathies. Expert Opin Drug Saf 5: 95–106, 2006